CMB Monaco is proud to renew its partnership with Cancer Research UK, the world’s leading cancer charity, dedicated to saving and improving lives with its research. On 20 November 2026, World Children’s Day, a percentage of all trading commissions will once again be donated directly to the charity to support research into cancers affecting children and young people.

In this joint interview, Francesco Grosoli, CEO of CMB Monaco, looks back at the results of last year’s initiative and explains why the bank is continuing this commitment, alongside Michelle Mitchell OBE, CEO of Cancer Research UK.

Q: Last year, CMB Monaco partnered with Cancer Research UK for the first time. Why renew this partnership in 2026

Francesco Grosoli: Last year, thanks to the generosity of our clients, we raised €23,357. That result belongs to all those who took part, and it gave us a strong reason to continue. Cancer research requires patience and long-term commitment, and so does our approach as a private bank. Renewing this partnership allows us to give our support a lasting dimension.

This is the fifth consecutive year that we dedicate our end-of-year initiative to children’s causes. This continuity reflects our values as a private bank rooted in family, legacy and care.

Q: How has this initiative evolved over the years?

Francesco Grosoli: Over the past four years, more than €123,000 has been raised, which is a considerable result. What matters most to us is that these funds represent a collective effort. Our clients and our employees each contribute in their own way, and together they have built something that extends far beyond banking.

Q: Michelle Mitchell, what did the support of CMB Monaco make possible last year?

Michelle Mitchell: As Francesco has mentioned, scientific research takes time. There is no quick fix, but we are beating cancer – step by step, day by day. At Cancer Research UK, we make discoveries about cancer that unlock new and better ways to beat it, and our vision is to bring about a world where everybody lives longer, better lives, free from the fear of cancer.

The funds raised by CMB Monaco and its clients last year went directly to our research into cancers that affect children and young people. Tackling these cancers is a critical focus of our research strategy.

Our research has helped double children’s cancer survival over the last 50 years in the UK, and we have played a role in around half of the world’s cancer drugs considered essential for children. But progress is hard won and cancer in children and young people is different to cancer in adults, so we need to do things differently. We want to transform the lives of children and young people with cancer by fundamentally shifting how we understand, detect and treat these cancers.

Q: Why do long-term partnerships matter in this field?

Michelle Mitchell: Long-term partnerships are particularly important in children’s and young people’s cancers because no single institution, charity or even country can generate enough data or recruit enough patients to answer the biggest research questions alone. Sustained partnerships enable researchers to work across borders, build the large-scale clinical trials needed to improve treatments, and generate the robust evidence required to change clinical practice.

As the UK’s largest charitable funder of research into children’s and young people’s cancers, Cancer Research UK is committed to driving progress in this area. However, historically it has been challenging to attract sufficient funding from other sources. That is starting to change, and long-term philanthropic partnerships will play a vital role in helping to provide the sustained investment needed to accelerate discoveries and, ultimately, improve outcomes and quality of life for children and young people affected by cancer.

Q: What message would you like to share with your clients and employees?

Francesco Grosoli: A sincere thank you for what you made possible last year, and an invitation to join us again on 20 November. Every contribution, whatever its size, helps move research forward for the youngest patients.